Dicycloverine hydrochloride with
aluminium hydroxide, magnesium
oxide and simeticone
The properties listed below are those particular to the
combination only. For the properties of the components
please consider, dicycloverine hydrochloride p. 61 ,
aluminium hydroxide p. 598 , simeticone p. 52.lINDICATIONS AND DOSE
Symptomatic relief of gastro-intestinal disorders
characterised by smooth muscle spasm
▶BY MOUTH
▶Child 12–17 years: 10 – 20 mL every 4 hours as requiredlINTERACTIONS→Appendix 1 : antacids.dicycloverine
lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Oral suspension
▶Kolanticon(Peckforton Pharmaceuticals Ltd)
Dicycloverine hydrochloride 500 microgram per 1 ml, Simeticone
4 mg per 1 ml, Magnesium oxide light 20 mg per 1 ml, Aluminium
hydroxide dried 40 mg per 1 mlKolanticon gel sugar-free|
200 mlp£ 4. 00 sugar-free| 500 mlp£ 6. 00eiiiiF 489Hyoscine butylbromide 13-Mar-2017
lINDICATIONS AND DOSE
Symptomatic relief of gastro-intestinal or genito-urinary
disorders characterised by smooth muscle spasm
▶BY MOUTH
▶Child 6–11 years: 10 mg 3 times a day
▶Child 12–17 years: 20 mg 4 times a day
Acute spasm|Spasm in diagnostic procedures
▶INITIALLY BY INTRAMUSCULAR INJECTION, OR BY SLOW
INTRAVENOUS INJECTION
▶Child 2–5 years: 5 mg, then (by intramuscular injection
or by slow intravenous injection) 5 mg after 30 minutes
if required, dose may be repeated more frequently in
endoscopy; maximum 15 mg per day
▶Child 6–11 years: 5 – 10 mg, then (by intramuscular
injection or by intravenous injection) 5 – 10 mg after
30 minutes if required, dose may be repeated more
frequently in endoscopy; maximum 30 mg per day
▶Child 12–17 years: 20 mg, then (by intramuscular
injection or by slow intravenous injection) 20 mg after
30 minutes if required, dose may be repeated more
frequently in endoscopy; maximum 80 mg per day
Excessive respiratory secretions in palliative care
▶BY MOUTH
▶Child 1 month–1 year: 300 – 500 micrograms/kg 3 – 4 times
a day (max. per dose 5 mg)
▶Child 2–4 years: 5 mg 3 – 4 times a day
▶Child 5–11 years: 10 mg 3 – 4 times a day
▶Child 12–17 years: 10 – 20 mg 3 – 4 times a day
▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS
INJECTION
▶Child 1 month–4 years: 300 – 500 micrograms/kg
3 – 4 times a day (max. per dose 5 mg)
▶Child 5–11 years: 5 – 10 mg 3 – 4 times a day
▶Child 12–17 years: 10 – 20 mg 3 – 4 times a day
Bowel colic (in palliative care)
▶BY MOUTH
▶Child 1 month–1 year: 300 – 500 micrograms/kg 3 – 4 times
a day (max. per dose 5 mg)
▶Child 2–4 years: 5 mg 3 – 4 times a day
▶Child 5–11 years: 10 mg 3 – 4 times a day
▶Child 12–17 years: 10 – 20 mg 3 – 4 times a day▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS
INJECTION
▶Child 1 month–4 years: 300 – 500 micrograms/kg
3 – 4 times a day (max. per dose 5 mg)
▶Child 5–11 years: 5 – 10 mg 3 – 4 times a day
▶Child 12–17 years: 10 – 20 mg 3 – 4 times a day
PHARMACOKINETICS
▶Administration by mouth is associated with poor
absorption.lUNLICENSED USETabletsnot licensed for use in children
under 6 years.Injectionnot licensed for use in children
(age range not specified by manufacturer).IMPORTANT SAFETY INFORMATION
MHRA/CHM ADVICE: HYOSCINE BUTYLBROMIDE (BUSCOPAN®)
INJECTION: RISK OF SERIOUS ADVERSE EFFECTS IN PATIENTS
WITH UNDERLYING CARDIAC DISEASE (FEBRUARY 2017)
The MHRA advises that hyoscine butylbromide injection
can cause serious adverse effects including tachycardia,
hypotension, and anaphylaxis; several reports have
noted that anaphylaxis is more likely to be fatal in
patients with underlying coronary heart disease.
Hyoscine butylbromide injection is contra-indicated in
patients with tachycardia and should be used with
caution in patients with cardiac disease; the MHRA
recommends that these patients are monitored and that
resuscitation equipment and trained personnel are
readily available.lCONTRA-INDICATIONS
▶With intramuscular use or intravenous useTachycardia
lINTERACTIONS→Appendix 1 : hyoscine
lSIDE-EFFECTS
▶UncommonSkin reactions
▶Frequency not knownDyspnoea.mydriasis
lPREGNANCYManufacturer advises avoid.
lBREAST FEEDINGAmount too small to be harmful.
lDIRECTIONS FOR ADMINISTRATION
▶With oral useFor administration bymouth, injection
solution may be used; content of ampoule may be stored in
a refrigerator for up to 24 hours after opening.
▶With intravenous useForintravenous injection, may be
diluted with Glucose 5 % or Sodium Chloride 0. 9 %; give
over at least 1 minute.
lPRESCRIBING AND DISPENSING INFORMATION
Palliative careFor further information on the use of
hyoscine butylbromide in palliative care, see
http://www.palliativedrugs.com/formulary/en/hyoscine-butylbromide.
html
lEXCEPTIONS TO LEGAL CATEGORYHyoscine butylbromide
tablets can be sold to the public for medically confirmed
irritable bowel syndrome, provided single dose does not
exceed 20 mg, daily dose does not exceed 80 mg, and pack
does not contain a total of more than 240 mg.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension, oral solution
Solution for injection
▶Buscopan(Sanofi)
Hyoscine butylbromide 20 mg per 1 mlBuscopan 20 mg/ 1 ml
solution for injection ampoules| 10 ampouleP£ 2. 92 DT = £ 2. 92
Tablet
▶Buscopan(Sanofi)
Hyoscine butylbromide 10 mgBuscopan 10 mg tablets|
56 tabletP£ 3. 00 DT = £ 3. 0062 Gastro-intestinal smooth muscle spasm BNFC 2018 – 2019
Gastro-intestinal system1